Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02607813
Title Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

LXH 254 + Spartalizumab

LXH 254

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Massachusetts General Hospital MGH Cancer Center Boston Massachusetts 02114 United States Details
Memorial Sloan Kettering Cancer Center SC - LXH254X2101 New York New York 10065 United States Details
UT M.D Anderson Cancer Center SC - LXH254X2101 Houston Texas 77030 United States Details
Novartis Investigative Site Toronto Ontario M5G 2C1 Canada Details
Novartis Investigative Site Paris Cedex 10 75475 France Details
Novartis Investigative Site Toulouse 31059 France Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Modena MO 41124 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Chuo ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Groningen 9713 GZ Netherlands Details
Medical Oncology, Erasmus MC Rotterdam 3075 CE Netherlands Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Madrid 28046 Spain Details
Novartis Investigative Site Zuerich 8091 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field